↓ Skip to main content

Treatment of gram - positive infections in critically ill patients

Overview of attention for article published in BMC Infectious Diseases, November 2014
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (90th percentile)
  • High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

blogs
1 blog
twitter
6 X users
facebook
5 Facebook pages
googleplus
1 Google+ user

Readers on

mendeley
139 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Treatment of gram - positive infections in critically ill patients
Published in
BMC Infectious Diseases, November 2014
DOI 10.1186/1471-2334-14-92
Pubmed ID
Authors

Cristina Vazquez-Guillamet, Marin H Kollef

Abstract

Gram-positive bacteria to include methicillin-resistant Staphylococcus aureus (MRSA), methicillin-susceptible Staphylococcus aureus (MSSA), and enterococci, to include vancomycin-resistant enterococci (VRE), display a remarkable array of resistance and virulence factors, which have contributed to their prominent role in infections of the critically ill. Over the last three decades infections with these pathogens has increased as has their overall resistance to available antimicrobial agents. This has led to the development of a number of new antibiotics for the treatment of Gram-positive bacteria. At present, it is important that clinicians recognize the changing resistance patterns and epidemiology of Gram-positive bacteria as these factors may impact patient outcomes. The increasing range of these pathogens, such as the emergence of community-associated MRSA clones, emphasizes that all specialties of physicians treating infections should have a good understanding of the infections caused by Gram-positive bacteria in their area of practice. When initiating empiric antibiotics, it is of vital importance that this therapy be timely and appropriate, as delays in treatment are associated with adverse outcomes. Although vancomycin has traditionally been considered a first-line therapy for serious MRSA infections, multiple concerns with this agent have opened the door for alternative agents demonstrating efficacy in this role. Similarly, the expansion of VRE as a pathogen in the ICU setting has required the development of agents targeting this important pathogen.

Timeline

Login to access the full chart related to this output.

If you don’t have an account, click here to discover Explorer

X Demographics

X Demographics

The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 139 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Mexico 1 <1%
United States 1 <1%
Unknown 137 99%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 21 15%
Researcher 18 13%
Student > Ph. D. Student 15 11%
Other 14 10%
Student > Postgraduate 14 10%
Other 24 17%
Unknown 33 24%
Readers by discipline Count As %
Medicine and Dentistry 54 39%
Pharmacology, Toxicology and Pharmaceutical Science 13 9%
Agricultural and Biological Sciences 11 8%
Immunology and Microbiology 7 5%
Biochemistry, Genetics and Molecular Biology 3 2%
Other 14 10%
Unknown 37 27%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 May 2015.
All research outputs
#2,405,468
of 22,771,140 outputs
Outputs from BMC Infectious Diseases
#719
of 7,668 outputs
Outputs of similar age
#36,159
of 361,884 outputs
Outputs of similar age from BMC Infectious Diseases
#16
of 195 outputs
Altmetric has tracked 22,771,140 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 7,668 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 361,884 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 195 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.